Clinical trial

1st Line Durvalumab in PS 2 NSCLC Patients

NCT03620669

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-12-04

PhasePHASE2

Study timeline

Study start (actual)2018-12-04Date precision: day

Registry last updated2025-08-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC Stage IVunresolved

NSCLC Stage IIIBunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Swiss Cancer Institutelead sponsor

Mapped research locations

BaselSwitzerland1 BernSwitzerland1 GenevaSwitzerland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03620669 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.